share_log

Gilead Sciences | 10-Q: Q2 2024 Earnings Report

Gilead Sciences | 10-Q: Q2 2024 Earnings Report

吉利德科学 | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/09 05:20

Moomoo AI 已提取核心信息

Gilead Sciences reported total revenues of $7.0 billion for Q2 2024, up 5% year-over-year, driven by strong performance in HIV, Oncology and Liver Disease portfolios. HIV product sales increased 3% to $4.7 billion, led by Biktarvy's 8% growth to $3.2 billion. Oncology revenues rose 15% to $841 million, with Trodelvy sales growing 23% to $320 million and Cell Therapy sales up 11% to $521 million.Net income increased 55% to $1.6 billion and diluted EPS rose to $1.29, compared to $1.0 billion and $0.83 in Q2 2023. The improvement was driven by lower operating expenses and higher revenues, partially offset by increased unrealized losses on equity securities. Product gross margin remained stable at 77.7%.For the first half of 2024, the company recorded a net loss of $2.6 billion, primarily due to a $3.9 billion charge related to the CymaBay acquisition and a $2.4 billion IPR&D impairment charge for NSCLC assets. The company maintained strong liquidity with $2.8 billion in cash and equivalents, despite significant investments in acquisitions and R&D during the period.
Gilead Sciences reported total revenues of $7.0 billion for Q2 2024, up 5% year-over-year, driven by strong performance in HIV, Oncology and Liver Disease portfolios. HIV product sales increased 3% to $4.7 billion, led by Biktarvy's 8% growth to $3.2 billion. Oncology revenues rose 15% to $841 million, with Trodelvy sales growing 23% to $320 million and Cell Therapy sales up 11% to $521 million.Net income increased 55% to $1.6 billion and diluted EPS rose to $1.29, compared to $1.0 billion and $0.83 in Q2 2023. The improvement was driven by lower operating expenses and higher revenues, partially offset by increased unrealized losses on equity securities. Product gross margin remained stable at 77.7%.For the first half of 2024, the company recorded a net loss of $2.6 billion, primarily due to a $3.9 billion charge related to the CymaBay acquisition and a $2.4 billion IPR&D impairment charge for NSCLC assets. The company maintained strong liquidity with $2.8 billion in cash and equivalents, despite significant investments in acquisitions and R&D during the period.
吉利德科学报告称2024年第二季度总收入为70亿美金，同比增长5%，这一增长得益于HIV、肿瘤学和肝病产品组合的强劲表现。HIV产品销售增长3%，达到47亿美金，其中Biktarvy增长8%，达到32亿美金。肿瘤学收入上涨15%，达到84100万美金，Trodelvy销售增长23%，达到32000万美金，电芯治疗销售增长11%，达到52100万美金。净利润增加55%，达到16亿美金，摊薄后每股收益上升至1.29美金，相较于2023年第二季度的10亿美金和0.83美金有所改善。改善的主要原因是营业费用降低和收入增加，部分被股权证券未实现损失增加所抵消。产品毛利率保持在77.7%。在2024年上半年，公司录得净亏损26亿美金，主要由于与CymaBay收购相关的39亿美金费用以及与NSCLC资产相关的24亿美金的知识产权和研发减值费用。尽管在此期间进行了大量的收购和研发投资，公司仍保持强劲的流动性，现金及现金等价物达28亿美金。
吉利德科学报告称2024年第二季度总收入为70亿美金，同比增长5%，这一增长得益于HIV、肿瘤学和肝病产品组合的强劲表现。HIV产品销售增长3%，达到47亿美金，其中Biktarvy增长8%，达到32亿美金。肿瘤学收入上涨15%，达到84100万美金，Trodelvy销售增长23%，达到32000万美金，电芯治疗销售增长11%，达到52100万美金。净利润增加55%，达到16亿美金，摊薄后每股收益上升至1.29美金，相较于2023年第二季度的10亿美金和0.83美金有所改善。改善的主要原因是营业费用降低和收入增加，部分被股权证券未实现损失增加所抵消。产品毛利率保持在77.7%。在2024年上半年，公司录得净亏损26亿美金，主要由于与CymaBay收购相关的39亿美金费用以及与NSCLC资产相关的24亿美金的知识产权和研发减值费用。尽管在此期间进行了大量的收购和研发投资，公司仍保持强劲的流动性，现金及现金等价物达28亿美金。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    施贵宝
    BMY
    -- 60.020
    默沙东
    MRK
    -- 89.230
    赛诺菲安万特
    SNY
    -- 55.820
    阿斯利康
    AZN
    -- 73.790
    艾伯维公司
    ABBV
    -- 205.290
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点